Oral Insulin Phase 1 Trials Begin
Novo Nordisk has initiated its first Phase 1 clinical trial with an oral insulin analog, NN1952, which was created using Merrion Pharmaceuticals' GIPET technology.
Novo Nordisk has initiated its first Phase 1 clinical trial with an oral insulin analog, NN1952, which was created using Merrion Pharmaceuticals’ GIPET technology.
There are many challenges with the development and production of a reliable insulin formulation for oral use. These include avoiding enzymatic degradation in the gastrointestinal tract, overcoming poor spontaneous insulin permeability over the intestinal wall, limiting variability of absorption (caused, for example, by interaction with food), and producing insulin at a sufficient scale cost-effectively.
NN1952 has been designed to address some of the key challenges relating to oral insulin delivery. The GIPET formulation technology from Merrion Pharmaceuticals helps facilitate insulin absorption from the gut.
NN1952 is not the only oral insulin formulation being tested. The Chinese State Food and Drug Administration (SFDA) has recently approved the investigational new drug application (IND) for Shanghai Biolaxy’s (Shanghai, China) oral insulin project (Nodlin). This IND approval allows Biolaxy to initiate its first Phase 1 clinical study.
Nodlin is developed with a patented bio-adhesive nanoparticle oral delivery (NOD) technology to overcome the barriers of oral insulin. Nodlin is the first candidate developed with NOD technology and is positioned as basal insulin formulation based on the preclinical data.
The Future of Cleanroom Construction: How Hybrid Solutions are Changing the Game
May 14th 2025Imagine a world where cleanroom facilities—essential for pharmaceutical manufacturing, biotechnology, and high-tech industries—are built with unparalleled speed, precision, and efficiency. That world is here, thanks to the hybrid construction approach. By blending traditional stick-built methods with modular and prefabricated solutions, companies are overcoming the limitations of conventional construction while ensuring compliance with stringent industry regulations. In this interview, we explore how hybrid cleanroom construction is transforming the industry, offering faster project timelines, improved quality control, and significant cost advantages. Join us as we delve into this game-changing approach with industry experts who are leading the charge in revolutionizing cleanroom infrastructure.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
